Acupressure for Chemotherapy-Induced Nausea and Vomiting: A Randomized Clinical Trial

Suzanne L. Dibble, DNSc, RN, Judy Luce, MD, Bruce A. Cooper, PhD, Jill Israel, RN, Misha Cohen, LAc, OMD, Brenda Nussey, BA, and Hope Rugo, MD

Purpose/Objectives: To compare differences in chemotherapy-induced nausea and vomiting (CINV) among three groups of women (acupressure, placebo acupressure, and usual care) undergoing chemotherapy for breast cancer.

Design: A multicenter, longitudinal, randomized clinical trial throughout one cycle of chemotherapy.

Setting: Ten community clinical oncology programs associated with the University of Texas M.D. Anderson Cancer Center and nine independent sites located throughout the United States.

Sample: 160 women who were beginning their second or third cycle of chemotherapy for breast cancer treatment and had moderate nausea intensity scores with their previous cycles.

Methods: Subjects were randomized to one of three groups: acupressure to P6 point (active), acupressure to SI3 point (placebo), or usual care only. Subjects in the acupressure group were taught to apply an acupressure wrist device by research assistants who were unaware of the active acupressure point. All subjects completed a daily log for 21 days containing measures of nausea and vomiting and recording methods (including antiemetics and acupressure) used to control these symptoms.

Main Research Variables: Acute and delayed nausea and vomiting.

Results: No significant differences existed in the demographic, disease, or treatment variables among the treatment groups. No significant differences were found in acute nausea or emesis by treatment group. With delayed nausea and vomiting, the acupressure group had a statistically significant reduction in the amount of vomiting and the intensity of nausea over time when compared with the placebo and usual-care groups. No significant differences were found between the placebo and usual-care groups in delayed nausea or vomiting.

Conclusions: Acupressure at the P6 point is a value-added technique in addition to pharmaceutical management for women undergoing treatment for breast cancer to reduce the amount and intensity of delayed CINV.

Implications for Nursing: Acupressure is a safe and effective tool for managing delayed CINV and should be offered to women undergoing chemotherapy for breast cancer.

In 2007, an estimated 178,480 women in the United States are expected to be diagnosed with breast cancer (American Cancer Society, 2007). Many women are treated with moderate to highly emetogenic chemotherapy, including doxorubicin and cyclophosphamide with or without 5-fluorouracil. Despite recent pharmaceutical advances in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), many patients continue to experience significant delayed nausea and some vomiting. Nausea and vomiting have been identified as contributing to patients’ reluctance to begin chemotherapy and may result in the discontinuation of potentially effective treatment strategies (Carr et al., 1985; Dibble, Casey, Nussey, Israel, & Luce, 2004; Dibble, Israel, Nussey, Casey, & Luce, 2003; Rhodes & McDaniel, 1997).

Small studies of acupressure (Dibble, Chapman, Mack, & Shih, 2000; Dundee & Yang, 1990; Stannard, 1989) have suggested that pressure on the nei guan (P6) points may be an effective method to reduce CINV in women undergoing chemotherapy. Some of the studies were cited in a recent Cochrane review (Ezzo et al., 2006) that supported the use of acupressure at P6 for nausea control.

Suzanne L. Dibble, DNSc, RN, is professor emerita at the Institute for Health and Aging in the School of Nursing at the University of California, San Francisco (UCSF), and president of Dibble Consulting Corporation in San Mateo, CA; Judy Luce, MD, is a professor in the Division of Hematology/Oncology in the School of Medicine at San Francisco General Hospital Medical Center; Bruce A. Cooper, PhD, is a senior statistician in the Office of Research and an associate adjunct professor in Community Health Systems at UCSF; Jill Israel, RN, is a research nurse in the Department of Pulmonary and Critical Care at San Francisco General Hospital Medical Center; Misha Cohen, LAc, OMD, is an assistant researcher in Integrative Medicine at the Institute for Health and Aging in the School of Nursing at UCSF, the research/education chair at the Quan Yin Healing Arts Center in San Francisco, and the clinic director of Chicken Soup Chinese Medicine in San Francisco; Brenda Nussey, BA, is a programmer/analyst at the Institute for Health and Aging in the School of Nursing at UCSF; and Hope Rugo, MD, is a professor in the Division of Hematology and Oncology in the Department of Medicine at UCSF. This study was funded by the National Cancer Institute (R01-84014) and the Community Clinical Oncology Program (U10 CA 045809-15). (Submitted July 2006. Accepted for publication March 4, 2007.)

Key Points . . .

➤ Nausea, especially delayed nausea, continues to be a problem for many women undergoing chemotherapy for breast cancer.
➤ The amount and intensity of nausea are greater among younger women.
➤ A numeric rating scale is an appropriate daily measure of delayed nausea.

ONCOLOGY NURSING FORUM – VOL 34, NO 4, 2007
813